EP3003443B1 - A system and a corresponding method for estimating respiratory drive of mechanically ventilated patients - Google Patents
A system and a corresponding method for estimating respiratory drive of mechanically ventilated patients Download PDFInfo
- Publication number
- EP3003443B1 EP3003443B1 EP14725961.8A EP14725961A EP3003443B1 EP 3003443 B1 EP3003443 B1 EP 3003443B1 EP 14725961 A EP14725961 A EP 14725961A EP 3003443 B1 EP3003443 B1 EP 3003443B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- patient
- respiratory
- drive
- response
- mechanical ventilation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000000241 respiratory effect Effects 0.000 title claims description 123
- 238000000034 method Methods 0.000 title description 32
- 230000004044 response Effects 0.000 claims description 93
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 79
- 239000000126 substance Substances 0.000 claims description 72
- 210000004369 blood Anatomy 0.000 claims description 54
- 239000008280 blood Substances 0.000 claims description 54
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 54
- 239000001569 carbon dioxide Substances 0.000 claims description 54
- 238000005399 mechanical ventilation Methods 0.000 claims description 47
- 230000003387 muscular Effects 0.000 claims description 45
- 238000009423 ventilation Methods 0.000 claims description 43
- 238000005259 measurement Methods 0.000 claims description 39
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 26
- 239000007789 gas Substances 0.000 claims description 25
- 230000036391 respiratory frequency Effects 0.000 claims description 22
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 22
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 230000008859 change Effects 0.000 claims description 12
- 230000004060 metabolic process Effects 0.000 claims description 12
- 230000003519 ventilatory effect Effects 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 9
- 230000002093 peripheral effect Effects 0.000 claims description 9
- 210000001519 tissue Anatomy 0.000 claims description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 230000003434 inspiratory effect Effects 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 238000004159 blood analysis Methods 0.000 claims description 6
- 238000006213 oxygenation reaction Methods 0.000 claims description 6
- 230000036961 partial effect Effects 0.000 claims description 6
- 229940075473 medical gases Drugs 0.000 claims description 5
- 238000004590 computer program Methods 0.000 claims description 4
- 238000013500 data storage Methods 0.000 claims description 2
- 108091008690 chemoreceptors Proteins 0.000 description 14
- 238000013178 mathematical model Methods 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 210000003205 muscle Anatomy 0.000 description 10
- 238000004088 simulation Methods 0.000 description 10
- 210000003019 respiratory muscle Anatomy 0.000 description 9
- 230000009471 action Effects 0.000 description 5
- 230000003139 buffering effect Effects 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 4
- 206010049565 Muscle fatigue Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 3
- 208000019693 Lung disease Diseases 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 239000010432 diamond Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000003722 extracellular fluid Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010062519 Poor quality sleep Diseases 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 206010069351 acute lung injury Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000012886 linear function Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000004220 muscle function Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 1
- 206010001029 Acute pulmonary oedema Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 208000024716 acute asthma Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 208000024584 respiratory abnormality Diseases 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0057—Pumps therefor
- A61M16/0066—Blowers or centrifugal pumps
- A61M16/0069—Blowers or centrifugal pumps the speed thereof being controlled by respiratory parameters, e.g. by inhalation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/021—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes operated by electrical means
- A61M16/022—Control means therefor
- A61M16/024—Control means therefor including calculation means, e.g. using a processor
- A61M16/026—Control means therefor including calculation means, e.g. using a processor specially adapted for predicting, e.g. for determining an information representative of a flow limitation during a ventilation cycle by using a root square technique or a regression analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/12—Preparation of respiratory gases or vapours by mixing different gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/0027—Accessories therefor, e.g. sensors, vibrators, negative pressure pressure meter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/003—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter
- A61M2016/0033—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter electrical
- A61M2016/0039—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter electrical in the inspiratory circuit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/003—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter
- A61M2016/0033—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter electrical
- A61M2016/0042—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter electrical in the expiratory circuit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0464—Cerebrospinal fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3331—Pressure; Flow
- A61M2205/3334—Measuring or controlling the flow rate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/20—Blood composition characteristics
- A61M2230/202—Blood composition characteristics partial carbon oxide pressure, e.g. partial dioxide pressure (P-CO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/20—Blood composition characteristics
- A61M2230/205—Blood composition characteristics partial oxygen pressure (P-O2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/20—Blood composition characteristics
- A61M2230/208—Blood composition characteristics pH-value
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/40—Respiratory characteristics
- A61M2230/42—Rate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/40—Respiratory characteristics
- A61M2230/43—Composition of exhalation
- A61M2230/432—Composition of exhalation partial CO2 pressure (P-CO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/40—Respiratory characteristics
- A61M2230/43—Composition of exhalation
- A61M2230/435—Composition of exhalation partial O2 pressure (P-O2)
Definitions
- the present invention relates to a system and a corresponding method for estimating the respiratory drive of mechanically ventilated patients. More particularly, for apportioning this respiratory drive into one, or more, components related to chemical drive - i.e. the drive due to the chemoreceptor response- and/or muscular drive - i.e. the contraction of respiratory muscles, for example the diaphragm.
- a device or system capable of performing mechanical ventilation is sometimes called an artificial breathing machine, a life support device, or, more popularly, a respirator.
- patients are ventilated using "support” modes. In these modes, patients have some respiratory drive and try to breathe themselves, with the patient then being “supported” with extra inspiratory volume or pressure.
- the patient's respiratory drive is controlled, primarily, by two factors.
- the first factor is the signalling from the brain to the respiratory muscles that they should contract such that a breath is taken. This signaling is due to a number of factors but paramount in these is the chemical signaling by the chemoreflex system. Adverse changes in oxygen, carbon dioxide and acid levels of blood and cerebral spinal fluid (CSF) are detected by the body chemoreceptors, which signal the brain to change the rate and depth of breathing. In health this signaling will be appropriate to normalize levels of oxygen, carbon dioxide and acidity of the blood and CSF. In disease, or in other situations such as the administration of opioids and other drugs, chemoreceptor response may be reduced, and signaling insufficient.
- CSF cerebral spinal fluid
- the chemical response to breathing is also modified by metabolism, such that a greater respiratory drive will be present in situations of higher CO 2 production; and in situations where the acid-base status of blood or CSF is acutely or chronically changed.
- the chronic changes in the buffering properties of CSF in patients with chronic lung disease are well known to reduce chemical drive to breathing via central chemoreceptor response.
- the second factor is the nature of the muscles.
- signals from the brain to the respiratory muscles that a breath is required would result in contraction of the respiratory muscles by the appropriate amount to ensure ventilator volumes, which normalize levels of oxygen, carbon dioxide and acidity of the blood and CSF.
- the respiratory muscles may be weakened or tired and as such unable to contract the appropriate amount.
- Reduced chemical drive could lead the doctor to consider reducing opioid therapy.
- Reduced muscular drive could lead the doctor to consider mobilisation of the patient.
- improved methods for apportioning respiratory drive to components related to chemical and/or muscular drive would be advantageous.
- US patent application 2010/0228142 discloses a method for determining dynamically a respiratory feature in a spontaneously breathing patient receiving mechanical ventilatory assist.
- the method comprises: modifying a level of mechanical ventilatory assist to the patient, measuring an airway pressure, detecting a change of gradient of the measured airway pressure and determining the respiratory feature based on the measured airway pressure upon detecting the change of gradient of the airway pressure.
- the method also comprises: measuring a respiratory neural drive of the patient and detecting a lowest level of the measured respiratory neural drive for determining the respiratory feature based on the detected lowest level of respiratory neural drive.
- An inherent disadvantage by this method is the need for measuring neural drive by an electrode in the diaphragm which is typically inserted into the oesophagus.
- US 2008/295839 discloses a ventilator control system for assisting the respiratory function of a patient under the direction of a clinician, the systems having a computerized, operation controller or control module or computing device that is in electronic communication with a intra-ventilator and or extra-ventilator electrical or data circuit or data network.
- US 2005/098178 discloses a a system and method for monitoring the ventilation support by a ventilator that is supplying breathing gas to patient a breathing gas toa patient via a breathing circuit that is in fluid communication with the lungs of the patient.
- D.S. Karbing et al. discloses evaluation of a computerized model-based decision support system (DSS) for its advice on inspired oxygen fraction, tidal volume and respiratory frequency.
- DSS computerized model-based decision support system
- the DSS was retrospectively evaluated in 16 intensive care patient cases, with physiological models fitted to the retrospective data and then used to simulate patient response to changes in therapy. Sensitivity of the DSS's advice to variations in cardiac output (CO) was evaluated.
- an improved way of estimating respiratory drive would be advantageous, and in particular a more efficient and/or reliable way of estimating respiratory drive would be advantageous.
- a system and a corresponding method are presented where baseline values of, or changes in the values of volume support or pressure support, in a mechanically ventilated patient, and measurement of the response in ventilator parameters, such as respiratory frequency, are used to estimate the patient's respiratory drive, and preferably to apportion this drive into one, or more, components related to chemical and muscular response.
- ventilator parameters such as respiratory frequency
- an object of the present invention relates to a system for estimating the total respiratory drive of a patient from changes in mechanical ventilator settings.
- one object of the invention relates to a system for apportioning a component of the respiratory drive due to chemical response from chemoreceptors.
- a further object of the invention relates to a system for apportioning a component of the respiratory drive due to muscular response for the respiratory muscles.
- the present disclosure relates to a mechanical ventilation system for respiration aid of an associated patient, the system being adapted for estimating one, or more, components of the respiratory drive (R_DRIVE) of said patient, the system comprising:
- the principle of the invention presented here is that measurement of changes ventilation frequency or volume in response to changes ventilator support settings can be used, in combination with mathematical physiological models, to identify chemoreceptor drive, muscular drive and/or the total respiratory drive which is beneficial to obtain for diagnostic and/or curative purposes.
- the physiological model (MOD) may comprise a component of the total respiratory drive being indicative of muscular response (R_MUSC).
- R_MUSC muscular response
- the physiological model (MOD) may comprise a component of the total respiratory drive being indicative of chemical response (R_CHEM), preferably a subcomponent indicative of the central chemical response and a subcomponent indicative of the peripheral chemical response.
- R_CHEM chemical response
- the chemical response of the respiratory drive is typically the dominating factor and is therefore important to evaluate.
- the control means may be arranged for estimating both the muscular response (R_MUS) and chemical response (R_CHEM) forming part of the total respiratory drive (R_DRIVE).
- the measurement means and the control means may be further arranged to measure an indication of muscular response (R_MUSC), such as by estimating or obtaining muscular drive from other measurement means or sources (e.g. previous values), such as an electrical measurement of the diaphragm, or similar.
- R_MUSC indication of muscular response
- control means may be arranged for estimating the muscular response (R_MUS) and chemical response (R_CHEM) by initially assuming one of the two responses; muscular response (R_MUS) or chemical response (R_CHEM), being a certain approximately constant level, preferably a normal level for said patient depending on the medical history and/or condition of the patient, and then subsequently iteratively solving for the other response, e.g. assuming normal muscular response and then solve for the chemical response as it will be explained below.
- R_MUS muscular response
- R_CHEM chemical response
- the mechanical ventilation system may assume that the muscular response is initially constant, preferably a normal level for said patient, and the chemical response may then be estimated, the estimated chemical response being subsequently applied for modelling a respiratory feedback to be compared with a measured respiratory feedback of the patient, this feedback being characterised by for example changes in respiratory volume or frequency, or measures of oxygenation or acid base-status of blood, or respiratory gasses. Any deviation between model simulated and measured feedback being an absolute or relative measure for an inadequate response capability of the patient.
- the said inadequate response capability of the patient may at least be a measure of the fatigue of the patient, though the inadequate response capability of the patient could also be interpreted to be a measure, or a component, of other reasons for poor respiratory muscle function such as medication with for example muscle relaxants, or other medications which reduce respiratory response through action on non-chemoreceptor mechanisms.
- the second data (D2) used in the physiological model (MOD) may be indicative for oxygenation and/or acid-base status of the blood, e.g. pHa, preferably being related to the influence of the acid-base status on the cerebrospinal fluid (CSF).
- the second data (D2) used in the physiological model (MOD) may, alternatively or additionally, be indicative for the metabolism of said patient, preferably the tissue production of carbon dioxide (CO 2 ).
- the physiological model (MOD) capable of estimating one, or more, components of the total respiratory drive (R_DRIVE) for the patient may be operationally connected to a medical decision support system (DSS), preferably for application in mechanical ventilation.
- DSS medical decision support system
- the DSS could be applied in connection with treatment plan, for therapy, and/or for diagnosis of the patient.
- the DSS could be the so-called INVENT system co-developed by one of the present inventors, cf. reference [5] and [6].
- the measurement means (M_G) may be arranged for measuring one or more of the following parameters consisting of: respiratory frequency (RR) or, equivalently, duration of breath (including duration of inspiratory or expiratory phase), and expiratory carbon dioxide levels (FECO 2 ), fraction of carbon dioxide in expired gas at the end of expiration, (FE'CO 2 ), partial pressure of carbon dioxide in expired gas (PECO 2 ), partial pressure of carbon dioxide in expired gas at the end of expiration (PE'CO 2 ), or equivalents thereof and/or combinations thereof.
- Other parameters applicable for respiratory response or feedback by a patient measurable in the expired air may also be applied within the context of the present invention once the general principle and teaching of the invention has been appreciated by the skilled person.
- the second data (D2) which may be obtainable from blood analysis (M_B) of said patient (P) may be one or more parameters consisting of: arterial blood pH (pHa), pressure of carbon dioxide level (PaCO 2 ), optionally measured transcutaneously (PtcC02), oxygen saturation of arterial blood (SaO2), pressure of oxygen in arterial blood (PpO2), or equivalents thereof and/or combinations thereof.
- Other parameters applicable, estimated or measurable in blood of a patient may also be applied within the context of the present invention once the general principle and teaching of the invention has been appreciated by the skilled person.
- the present invention is advantageous in that the respiratory drive may be estimated without using a measurement of the electrical activity of the diaphragm of the patient, cf. US patent application 2010/0228142 where this is performed.
- control means may be capable of changing the level from one value to another value in one, or more, volume and/or pressure parameters of the ventilator means (Vt_SET) so as to detect the subsequent changes in the respiratory feedback of said patient by the measurement means.
- Vt_SET volume and/or pressure parameters of the ventilator means
- control means may be alternatively be capable of performing a change in one, or more, volume and/or pressure parameters of the ventilator means (Vt_SET) so as to detect associated changes in the respiratory feedback of said patient by the measurement means while performing said change.
- Vt_SET volume and/or pressure parameters of the ventilator means
- control means may be capable of changing one, or more, volume and/or pressure parameters of the ventilator means by changing the inspiratory volume (Vt_SET) and/or the inspiratory pressure set by the ventilator means. It is important to distinguish between the settings for pressure or volume for the mechanical ventilator, and, on the other hand, the actual volume inhaled or expired by the patient, as it will be understood by a person skilled in mechanical ventilation of patients.
- the present disclosure relates to method for operating a mechanical ventilation system for respiration aid of an associated patient, the method being adapted for estimating one, or more, components of the respiratory drive (R_DRIVE) of said patient, the method comprising:
- the present disclosure relates to a computer program product being adapted to enable a computer system comprising at least one computer having data storage means in connection therewith to control a ventilation system according to the first and/or second aspect.
- this aspect of the present disclosure may differ from the method of the second aspect in that the third aspect is directed to controlling and/or cooperating with the ventilator means (VENT), the control means (CON), and measurement means (M_G) i.e. instead of providing them.
- This aspect of the present disclosure is particularly, but not exclusively, advantageous in that the present disclosure may be accomplished by a computer program product enabling a computer system to carry out the operations of the ventilation system of the first aspect of the present disclosure when down- or uploaded into the computer system.
- a computer program product may be provided on any kind of computer readable medium, or through a network.
- FIG. 1 is a schematic drawing of a mechanical ventilation system 10 for respiration aid of an associated patient 5, P, the system being adapted for estimating the respiratory drive R_DRIVE of the patient.
- the system comprises ventilator means 11, VENT capable of mechanical ventilating said patient with air and/or one or more medical gases, e.g. oxygen and/or nitrogen.
- ventilator means 11, VENT capable of mechanical ventilating said patient with air and/or one or more medical gases, e.g. oxygen and/or nitrogen.
- Conventional ventilator systems currently available may be modified or adapted for working in the context of the present invention.
- control means 12, CON is comprised in the system 10, the ventilator means 11 being controllable by said control means 10 by operational connection thereto, e.g. appropriate wirings and interfaces as it will be appreciated by the skilled person working with mechanical ventilation.
- measurement means 11a, M_G are arranged for measuring the respiratory feedback of said patient in the expired gas 6 in response to the mechanical ventilation, e.g. respiratory frequency or fraction of expired carbon dioxide commonly abbreviated FECO 2 , cf. list of some well-known abbreviations below.
- the measurement means are shown as forming part of the ventilator means 11, but could alternatively form an independent entity with respect to the ventilator means without significantly change the basic principle of the present invention.
- the measurement means M_G are capable of delivering first data D1 to the control means 12 CON by appropriate connection, by wire, wirelessly or by other suitably data connection.
- the control means 12 CON is also capable of operating the ventilation means by providing ventilatory assistance so that said patient 5 P is at least partly breathing spontaneously, and, when providing such ventilatory assistance, the control means being capable of changing one, or more, volume and/or pressure parameters Vt_SET of the ventilator means so as to detect changes in the respiratory feedback in general of the patient by the measurement means M_G.
- the control means is further being arranged for receiving second data D2, preferably obtainable from blood analysis of said patient performed by blood measurement means M_B 20, the second data being indicative of the respiratory feedback in the blood of said patient, e.g. pHa, PACO2, PA02 etc.
- second data D2 preferably obtainable from blood analysis of said patient performed by blood measurement means M_B 20
- the second data being indicative of the respiratory feedback in the blood of said patient, e.g. pHa, PACO2, PA02 etc.
- the by blood measurement means M_B 20 is not necessarily comprised in the ventilator system 10 according to the present invention. Rather, the system 10 is adapted for receiving second data D2 from such an entity or device as schematically indicated by the connecting arrow. It is however contemplated that a blood measurement means M_B could be comprised in the system 10 and integrated therein.
- the mechanical ventilator system comprises at least the ventilator means VENT 10, the measurement means M_G 11a, and the control means CON 12.
- the physiological model MOD is implemented on the control means,
- the second data D2 could be estimated or guessed values being indicative of the respiratory feedback in the blood of said patient, preferably based on the medical history and/or present condition of the said patient.
- values from previously could form the basis of such estimated guess for second data D2.
- the control means is adapted for using both the first data D1 indicative of changes of respiratory feedback in expired air 6, and the second data D2 indicative of the respiratory feedback in the blood 7, in a physiological model MOD capable of estimating one, or more, components of the total respiratory drive R_DRIVE for the patient 6 as schematically indicated in the box 13.
- the respiratory drive R_DRIVE may be outputted to an appropriate human- machine interface 13 for displaying the result, e.g. a computer with a screen therefore.
- the respiratory drive output R_DRIVE and/or its components may be communicated to a decision support system DSS 14 for use in connection with mechanical ventilation of patients, optionally for treatment and/or diagnostic purposes.
- Figure 2 illustrates an example of the structure a physiological model used in the method. It consists of model components representing the gas exchange of the lungs and the acid-base chemistry of the blood, components representing the acid-base of cerebrospinal fluid (CSF) and the resulting chemical respiratory drive, and the net effect of this chemical drive ventilation according to the action of respiratory muscles.
- CSF cerebrospinal fluid
- Figure 3 illustrates the model simulated response of a patient to changes in ventilator support, in this case volume support, represented as the volume of ventilation provided to the patient per breath (Vt), i.e. the variable on the x-axis of each of the subfigures in figure 3 .
- Alveolar ventilation (VA) could be plotted instead of tidal ventilation with no apparent differences in the method.
- VA the expected respiratory frequency
- FE'CO 2 end tidal carbon dioxide
- This response profile can be used to determine the total respiratory drive, and the components of chemical and muscular response. It is important to note that two factors separate this approach from those presented previously.
- the first is that no measure of the electrical activity of the diaphragm is used to assess the muscular drive to breathing.
- the second is that the simulated response to changes in ventilator support due to chemical drive can be accounted for by several physiological factors. This is only possible because of the physiological model, including factors contributing to the chemical drive describing: metabolism, and in particular the tissue production of CO 2 ; the acid-base status of blood which modifies peripheral chemoreceptor drive; and the acid base status of CSF which modifies central chemoreceptor drive. These aspects have not been accounted for previously, e.g. US patent application 2010/0228142 which is based upon diaphragm electrical activity.
- Figures 3a, 3b and 3c of the present application illustrate two different situations of a normal (solid line) and reduced (dashed line) total respiratory drive. Reducing the total respiratory drive modifies the position of the curves and lines representing these three variables.
- Estimation of the parallel shift of the three solid lines to the three dashed lines provides data which enables estimation of changes in the total respiratory drive.
- FIG. 3 illustrate the situation where patients muscle strength cannot respond adequately to reduction in volume support and respiratory frequency increases only partially, pH falls and FE'CO 2 increases.
- the alveolar ventilation predicted by the chemical drive (VAexp, figure 6 ) cannot be maintained by the muscles such that the true alveolar ventilation is lower and as a consequence pH falls and FE'CO 2 increases.
- This can be implemented by multiplying the alveolar ventilation predicted by the chemical model with a fraction (fM, figure 6 ) between 0 and 1, where 0 represents no muscle action and 1 muscle action sufficient to allow alveolar ventilation consistent with the respiratory drive.
- the quantification of the change in total respiratory drive and the components due to chemical and muscular response can be performed either via shifts in the measured curves or by analysing the responses illustrated in figure 3 using mathematical models, similar in structure to figure 2 and in details to figure 6 .
- Estimation of mathematical model parameters can then provide quantification of total respiratory drive and in addition chemical drive and/or muscular drive. It is thus to be understood that any combination of the total drive, the chemical drive (incl. sub-components) and the muscular drive (incl. sub-components) may be provided as a result of applying the present invention as described above, the drive components not being provided as results may possibly be applied as intermediate result(s), e.g. the total respiratory drive may be an intermediate result for finding the components of muscular drive and/or chemical drive.
- the overall principle of the method is then that changes in support mode settings which result in changes in tidal volume and respiratory frequency and or acid base status of blood or respiratory gasses can be used to estimate respiratory drive, and optionally apportion that to components related to chemical and muscular drive.
- the present disclosure thus relates to a method for determining respiratory drive and apportioning this to components related to chemical and muscular response.
- the present disclosure comprises measuring the level of ventilation volume or pressure, and one or more of the following variables respiratory frequency, arterial blood pH or carbon dioxide level, and expiratory carbon dioxide levels.
- the present disclosure further comprises changing ventilation volume or pressure and evaluating the changes in the following variables respiratory frequency, arterial blood pH or carbon dioxide level.
- the method further comprises analysis of these data in terms of mathematical models or curve shifts to determine respiratory drive.
- the method further comprises analysis of these data in terms of mathematical models or curve shifts to determine the component of respiratory drive due to chemical response.
- the method further comprises that measurements of metabolism and acid-base status of the blood or CSF can be accounted for in the component of respiratory drive due to chemical response.
- the method further comprises analysis of these data in terms of mathematical models or curve shifts to determine the component of respiratory drive due to response of the muscular system involved in breathing.
- the level of carbon dioxide in respiratory gas may be provided by measurements of FECO 2 , PECO 2 , FE'CO 2 , PE'CO 2 or other equivalent measures available to the skilled person.
- the present invention may be beneficially applied when the individual is a normal person, a person under mechanical ventilation in general, or suffers from one or more respiratory diseases or abnormalities, including primary and secondary lung diseases, such as chronic obstructive pulmonary disease (COPD), acute lung injury, acute respiratory distress syndrome, pulmonary edema, or asthma.
- primary and secondary lung diseases such as chronic obstructive pulmonary disease (COPD), acute lung injury, acute respiratory distress syndrome, pulmonary edema, or asthma.
- COPD chronic obstructive pulmonary disease
- Other related or similar diseases/conditions for which the present invention may be advantageously applied are also contemplated.
- the invention can be implemented by means of hardware, software, firmware or any combination of these.
- the invention or some of the features thereof can also be implemented as software running on one or more data processors and/or digital signal processors.
- the individual elements of an embodiment of the invention may be physically, functionally and logically implemented in any suitable way such as in a single unit, in a plurality of units or as part of separate functional units.
- the invention may be implemented in a single unit, or be both physically and functionally distributed between different units and processors.
- FIGs 4 and 5 exemplify the technique using data collected from two patients (one for each figure).
- plots are shown of changes in tidal volume (Vt) against A) respiratory frequency, B) end tidal CO 2 and C) arterial pH.
- the dashed curve in figure 4A represents the model simulated response of these variables assuming normal muscular and chemical response, normal values of metabolism, e.g. rate of tissue CO 2 production, and normal values of the acid-base status of blood and CSF.
- Stars, solid circles, crosses, diagonal crosses, open circles and triangles on plots 4A-C represent data collected at different values of Vt, with each symbol representing a different value of ventilator setting on the ventilator, Vt_SET. It should be noted this data has been collected and plotted with volume as a variable, but in clinical practise the pressure is often applied as the variable instead. This is however equivalent as the skilled person will understand, and does not change the overall principle and teaching of the present invention.
- Solid curves on plots 4A-C represent model simulations when the chemical response is adapted to the individual patient, but assuming normal muscular response.
- This adaptation to chemical response includes: a) inputting the rate of CO 2 production into the physiological model for that individual patient, where CO 2 production can be measured from respiratory gas composition and flow; b) inputting the acid-base status of blood into the model and from this calculating the state of CSF acid-base status, where acid-base status is measured, for example, from a blood sample.
- any factors in the response is not explained by changes in CO 2 production or abnormal acid-base status are then accounted for by fitting the physiological mathematical model to the measured data shown on figure 4A .
- This model fitting can be performed using standard least-square techniques where model parameters such as those describing thresholds or gains in central or peripheral chemical drive are adjusted until the model provides a best fit to the data as the minimum sum of squared differences between model predictions and measured data.
- This model fitting can be performed for data collected at a single setting of mechanical ventilation, or over a data set collected at several different settings as illustrated by each of the symbols on figure 4A .
- plots are shown of changes in tidal volume (Vt) against (a and e) respiratory frequency, and (b and f) arterial pH, and (c and g) end tidal CO 2 .
- the dashed curve in all subplots of figure 5 represent the model simulated response of these variables assuming normal muscular and chemical response, normal values of metabolism, e.g. rate of tissue CO 2 production, and normal values of the acid-base status of blood and CSF.
- Triangles, open circles, diagonal crosses, vertical crosses, diamonds and stars represent data collected or model simulations at different values of Vt, with each symbol representing a different value of ventilator setting on the ventilator, Vt_SET.
- This adaptation to chemical response includes: a) inputting the rate of CO 2 production into the physiological model for that individual patient, where CO 2 production can be measured from respiratory gas composition and flow; b) inputting the acid-base status of blood into the model and from this calculating the state of CSF acid-base status, where acid-base status is measured, for example, from a blood sample.
- any factors in the response is not explained by changes in CO 2 production or abnormal acid-base status are then accounted for by fitting the physiological mathematical model to the measured data shown on figures 5 a-c .
- This model fitting can be performed using standard least-square techniques where model parameters such as those describing thresholds or gains in central or peripheral chemical drive are adjusted until the model provides a best fit to the data as the minimum sum of squared differences between model predictions and measured data.
- This model fitting can be performed for data collected at a single setting of mechanical ventilation, or over a data set collected at several different settings as illustrated by each of the symbols on figures 5 a-c . It can be seen for this patient that fitting the chemical drive model alone results in simulations (symbols connected with dotted lines) which match measurements (symbols connected with solid lines) very well for the highest 4 levels of Vt, i.e. for levels represented by triangles, open circles, diagonal crosses, and vertical crosses.
- the model of chemical drive was adapted to the patient to describe the respiratory frequency, end tidal CO2 and arterial pH changes following changes in Vt as described above accounting for CO 2 production, acid-base status in blood and CSF and by fitting the model to the data to estimate parameters describing the threshold and gain of central chemoreceptor response.
- the shift illustrated by the arrow in figure 4a (labelled I) represents the change in chemical respiratory drive from normal seem in this patient due to all these factors in the mathematical model.
- the shift illustrated by the arrows in plots 4b and 4c, and labelled II represents changes in pH and PCO 2 characteristic of muscle fatigue and hence reduced muscle drive.
- These shifts can be represented graphically as here, or by using values of physiological model parameters. These parameters can, for example, describe weighting of the calculated chemical drive so as to reduce the effect of chemical response.
- data describing the response to changes in respiratory tidal volume can be used to identify changes in respiratory drive, including those that can be apportioned to changes in chemical and muscular response and that chemical drive can be measured components accounting for metabolism and acid-base status and model parameters describing regulation of chemoreceptors.
- FIG. 6 illustrates the set of mathematical model components of a decision support system (DSS) including the mathematical representation in the form of physiological model of respiratory control and muscle function that may be applied in the context of the present invention.
- DSS decision support system
- the DSS includes models of: pulmonary gas exchange (A); acid-base status and oxygenation of blood (B); acid-base status of CSF (C); circulation and blood in arterial and mixed venous pools (D); interstitial fluid and tissue buffering, and metabolism (E); chemoreflex model of respiratory control (F); muscular function (G); and ventilation (H).
- A pulmonary gas exchange
- B acid-base status and oxygenation of blood
- C acid-base status of CSF
- D circulation and blood in arterial and mixed venous pools
- D interstitial fluid and tissue buffering, and metabolism
- E chemoreflex model of respiratory control
- G muscular function
- ventilation H
- Figure 6 illustrates the set of mathematical model components of INVENT including the mathematical representation of respiratory control (A-H).
- Figure 6A illustrates the structure of the model of ventilation and pulmonary gas exchange.
- Figure 6B illustrates the structure of the model of oxygenation and acid-base status in the blood.
- Figure 6 C illustrates Duffin's model of CSF with appropriate model constants [3, 4].
- This model includes mass-action equations describing water, phosphate and albumin dissociation plus the formation of bicarbonate and carbonate, and an equation representing electrical neutrality (equations 1-6).
- equation (7) is used to describe the equilibration of PCO 2 with arterial blood across the blood-brain barrier.
- Equation (8) is a modification to Duffin's model which allows calibration of the CSF to conditions where blood bicarbonate, and hence buffer base (BB) or strong ion difference (SID) are modified, such as metabolic acidosis where blood bicarbonate is reduced, or chronic lung disease where blood bicarbonate is increased.
- BB buffer base
- SID strong ion difference
- the model illustrated in figure 6 includes compartments representing CO 2 transport and storage including the arterial and venous compartments, and circulation represented as cardiac output (Q) ( figure 5D ).
- Figure 6E illustrates the model of interstitial fluid and tissue buffering, and metabolism included in the system. This includes oxygen consumption (VO 2 ) and carbon dioxide production (VCO 2 ).
- Figure 6F illustrates the model of respiratory control of Duffin, i.e. equations 9 - 12.
- Alveolar ventilation is modeled as a peripheral and central chemoreflex response to arterial and cerebrospinal fluid (CSF) hydrogen ion concentration ([H + a ] and [H + csf ]) plus wakefulness drive.
- Equation (9) describes the peripheral drive (Dp) as a linear function of the difference between [H + a ] and the peripheral threshold (Tp).
- the slope of this function (Sp) represents the sensitivity of the peripheral chemoreceptors.
- Equation (11) describes central drive (Dc) as a linear function of the difference between [H + csf ] and the central threshold (Tc).
- the slope of this function (Sc) represents the sensitivity of central chemoreceptors.
- Equation (12) describes the expected alveolar ventilation as the sum of the two chemoreflex drives and the wakefulness drive (Dw).
- Figure 6G represents the muscular action on alveolar ventilation.
- the calculated alveolar ventilation from the respiratory control equations ( figure 6F ) is scaled according to a constant (0 ⁇ fM ⁇ 1) to calculate the alveolar ventilation applied by the muscles.
- a value of fM ⁇ 1 illustrates that the muscle cannot deliver the respiratory drive calculated by the chemical control model.
- Equation 14 describes the minute ventilation as alveolar ventilation plus ventilation of the dead space, that is equal to the product of tidal volume (Vt) and respiratory frequency (f).
- the model described above can be used to simulate respiratory control.
- the model enables simulation of the control of alveolar ventilation taking into account pulmonary gas exchange, blood and CSF acid-base status, circulation, tissue and interstitial buffering, and metabolism.
- FIG 7 is a schematic flow chart of a method according to the invention.
- the present disclosure thus relates to a method for operating a mechanical ventilation system 10 for respiration aid of an associated patient 5, P, the method being adapted for estimating the respiratory drive R_drive of said patient, the method comprising:
- the present disclosure relates to a system 10 and a corresponding method for estimating the respiratory drive,R_DRIVE, of mechanically ventilated patients, and for preferably apportioning this respiratory drive into one, or more, components related to the chemical drive - i.e. the drive due to the chemoreceptor response- and/or the muscular drive - i.e. the contraction of respiratory muscles, for example the diaphragm.
- the principle of the invention is that respiratory drive can be obtained from measuring the patient's response to small changes in mechanical ventilation settings, Vt_SET, and that this can be apportioned into chemical and/or muscular effects depending upon the changes in respiratory frequency, and/or arterial or end tidal CO 2 levels, and/or arterial blood pH, as indicated in Figure 1 .
Landscapes
- Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Description
- The present invention relates to a system and a corresponding method for estimating the respiratory drive of mechanically ventilated patients. More particularly, for apportioning this respiratory drive into one, or more, components related to chemical drive - i.e. the drive due to the chemoreceptor response- and/or muscular drive - i.e. the contraction of respiratory muscles, for example the diaphragm.
- Patients residing at the intensive care unit typically receive mechanical support for their ventilation. Selecting the appropriate level of mechanical ventilation is not trivial, and it has been shown that appropriate settings can reduce mortality [1].
- Notice that a device or system capable of performing mechanical ventilation is sometimes called an artificial breathing machine, a life support device, or, more popularly, a respirator.
- Typically, patients are ventilated using "support" modes. In these modes, patients have some respiratory drive and try to breathe themselves, with the patient then being "supported" with extra inspiratory volume or pressure. The patient's respiratory drive is controlled, primarily, by two factors.
- The first factor is the signalling from the brain to the respiratory muscles that they should contract such that a breath is taken. This signaling is due to a number of factors but paramount in these is the chemical signaling by the chemoreflex system. Adverse changes in oxygen, carbon dioxide and acid levels of blood and cerebral spinal fluid (CSF) are detected by the body chemoreceptors, which signal the brain to change the rate and depth of breathing. In health this signaling will be appropriate to normalize levels of oxygen, carbon dioxide and acidity of the blood and CSF. In disease, or in other situations such as the administration of opioids and other drugs, chemoreceptor response may be reduced, and signaling insufficient. The chemical response to breathing is also modified by metabolism, such that a greater respiratory drive will be present in situations of higher CO2 production; and in situations where the acid-base status of blood or CSF is acutely or chronically changed. For example, the chronic changes in the buffering properties of CSF in patients with chronic lung disease are well known to reduce chemical drive to breathing via central chemoreceptor response.
- The second factor is the nature of the muscles. In health, signals from the brain to the respiratory muscles that a breath is required, would result in contraction of the respiratory muscles by the appropriate amount to ensure ventilator volumes, which normalize levels of oxygen, carbon dioxide and acidity of the blood and CSF. In disease, the respiratory muscles may be weakened or tired and as such unable to contract the appropriate amount.
- The degree to which patients on mechanical ventilation should be supported depends upon their respiratory drive i.e. their own capability to control respiration. Patients with reduced drive will require extra support through greater volume or pressure levels. Patients with more normal levels of drive could receive reduced support, potentially enabling then to be weaned from mechanical ventilation more quickly. As weaning takes up a large portion of the time spent on mechanical ventilation [2], rapid appropriate weaning may be very beneficial. Hence, improved methods for estimating respiratory drive would be advantageous.
- A deeper understanding of the reasons for reduced respiratory drive could also be beneficial. Reduced chemical drive could lead the doctor to consider reducing opioid therapy. Reduced muscular drive could lead the doctor to consider mobilisation of the patient. Hence, improved methods for apportioning respiratory drive to components related to chemical and/or muscular drive would be advantageous.
-
US patent application 2010/0228142 (invented by Christer Sinderby, assigned to Maquet Critical Care) discloses a method for determining dynamically a respiratory feature in a spontaneously breathing patient receiving mechanical ventilatory assist. The method comprises: modifying a level of mechanical ventilatory assist to the patient, measuring an airway pressure, detecting a change of gradient of the measured airway pressure and determining the respiratory feature based on the measured airway pressure upon detecting the change of gradient of the airway pressure. Furthermore, the method also comprises: measuring a respiratory neural drive of the patient and detecting a lowest level of the measured respiratory neural drive for determining the respiratory feature based on the detected lowest level of respiratory neural drive. An inherent disadvantage by this method is the need for measuring neural drive by an electrode in the diaphragm which is typically inserted into the oesophagus. -
US 2008/295839 discloses a ventilator control system for assisting the respiratory function of a patient under the direction of a clinician, the systems having a computerized, operation controller or control module or computing device that is in electronic communication with a intra-ventilator and or extra-ventilator electrical or data circuit or data network. -
US 2005/098178 discloses a a system and method for monitoring the ventilation support by a ventilator that is supplying breathing gas to patient a breathing gas toa patient via a breathing circuit that is in fluid communication with the lungs of the patient. - D.S. Karbing et al. ("Retroscpective evaluation of a decision support system for controlled mechanical ventilation", Medical & Biological engineering & computing, Springer, vol. 50, no. 1, Nov 2011, pp. 43-51) discloses evaluation of a computerized model-based decision support system (DSS) for its advice on inspired oxygen fraction, tidal volume and respiratory frequency. The DSS was retrospectively evaluated in 16 intensive care patient cases, with physiological models fitted to the retrospective data and then used to simulate patient response to changes in therapy. Sensitivity of the DSS's advice to variations in cardiac output (CO) was evaluated.
- Hence, an improved way of estimating respiratory drive would be advantageous, and in particular a more efficient and/or reliable way of estimating respiratory drive would be advantageous.
- A system and a corresponding method are presented where baseline values of, or changes in the values of volume support or pressure support, in a mechanically ventilated patient, and measurement of the response in ventilator parameters, such as respiratory frequency, are used to estimate the patient's respiratory drive, and preferably to apportion this drive into one, or more, components related to chemical and muscular response. In this way, a greater understanding of the patient can be obtained during mechanical ventilation, which may improve diagnosis and the selection of mechanical ventilator settings.
- Thus, an object of the present invention relates to a system for estimating the total respiratory drive of a patient from changes in mechanical ventilator settings.
- Thus, one object of the invention relates to a system for apportioning a component of the respiratory drive due to chemical response from chemoreceptors.
- Thus, a further object of the invention relates to a system for apportioning a component of the respiratory drive due to muscular response for the respiratory muscles.
- In a first aspect, the present disclosure relates to a mechanical ventilation system for respiration aid of an associated patient, the system being adapted for estimating one, or more, components of the respiratory drive (R_DRIVE) of said patient, the system comprising:
- ventilator means (VENT) capable of mechanical ventilating said patient with air and/or one or more medical gases,
- control means (CON), the ventilator means being controllable by said control means by operational connection thereto, and
- measurement means (M_G) arranged for measuring the respiratory feedback of said patient in the expired gas in response to the mechanical ventilation, the measurement means being capable of delivering first data (D1) to said control means,
- the first data (D1) indicative of changes of respiratory feedback in expired air, and
- the second data (D2) indicative of the respiratory feedback in the blood, in a physiological model (MOD) capable of estimating one, or more, components (R_MUSC, R_CHEM) of the total respiratory drive (R_DRIVE) for the patient.
- The principle of the invention presented here is that measurement of changes ventilation frequency or volume in response to changes ventilator support settings can be used, in combination with mathematical physiological models, to identify chemoreceptor drive, muscular drive and/or the total respiratory drive which is beneficial to obtain for diagnostic and/or curative purposes.
- Advantageously, the physiological model (MOD) may comprise a component of the total respiratory drive being indicative of muscular response (R_MUSC). This is an advantage because previously the muscular response could be difficult to measure or evaluate. Alternatively or additionally, the physiological model (MOD) may comprise a component of the total respiratory drive being indicative of chemical response (R_CHEM), preferably a subcomponent indicative of the central chemical response and a subcomponent indicative of the peripheral chemical response. The chemical response of the respiratory drive is typically the dominating factor and is therefore important to evaluate. Beneficially, the control means may be arranged for estimating both the muscular response (R_MUS) and chemical response (R_CHEM) forming part of the total respiratory drive (R_DRIVE).
- In another embodiment of the mechanical ventilation system, the measurement means and the control means may be further arranged to measure an indication of muscular response (R_MUSC), such as by estimating or obtaining muscular drive from other measurement means or sources (e.g. previous values), such as an electrical measurement of the diaphragm, or similar.
- In an embodiment, the control means may be arranged for estimating the muscular response (R_MUS) and chemical response (R_CHEM) by initially assuming one of the two responses; muscular response (R_MUS) or chemical response (R_CHEM), being a certain approximately constant level, preferably a normal level for said patient depending on the medical history and/or condition of the patient, and then subsequently iteratively solving for the other response, e.g. assuming normal muscular response and then solve for the chemical response as it will be explained below. In one particular embodiment of this, the mechanical ventilation system may assume that the muscular response is initially constant, preferably a normal level for said patient, and the chemical response may then be estimated, the estimated chemical response being subsequently applied for modelling a respiratory feedback to be compared with a measured respiratory feedback of the patient, this feedback being characterised by for example changes in respiratory volume or frequency, or measures of oxygenation or acid base-status of blood, or respiratory gasses. Any deviation between model simulated and measured feedback being an absolute or relative measure for an inadequate response capability of the patient. The said inadequate response capability of the patient may at least be a measure of the fatigue of the patient, though the inadequate response capability of the patient could also be interpreted to be a measure, or a component, of other reasons for poor respiratory muscle function such as medication with for example muscle relaxants, or other medications which reduce respiratory response through action on non-chemoreceptor mechanisms.
- In one embodiment, the second data (D2) used in the physiological model (MOD) may be indicative for oxygenation and/or acid-base status of the blood, e.g. pHa, preferably being related to the influence of the acid-base status on the cerebrospinal fluid (CSF). In another embodiment, the second data (D2) used in the physiological model (MOD) may, alternatively or additionally, be indicative for the metabolism of said patient, preferably the tissue production of carbon dioxide (CO2).
- In one particular embodiment, the physiological model (MOD) capable of estimating one, or more, components of the total respiratory drive (R_DRIVE) for the patient may be operationally connected to a medical decision support system (DSS), preferably for application in mechanical ventilation. The DSS could be applied in connection with treatment plan, for therapy, and/or for diagnosis of the patient. As an example, the DSS could be the so-called INVENT system co-developed by one of the present inventors, cf. reference [5] and [6].
- In another particular embodiment, the measurement means (M_G) may be arranged for measuring one or more of the following parameters consisting of: respiratory frequency (RR) or, equivalently, duration of breath (including duration of inspiratory or expiratory phase), and expiratory carbon dioxide levels (FECO2), fraction of carbon dioxide in expired gas at the end of expiration, (FE'CO2), partial pressure of carbon dioxide in expired gas (PECO2), partial pressure of carbon dioxide in expired gas at the end of expiration (PE'CO2), or equivalents thereof and/or combinations thereof. Other parameters applicable for respiratory response or feedback by a patient measurable in the expired air may also be applied within the context of the present invention once the general principle and teaching of the invention has been appreciated by the skilled person.
- In another embodiment, the second data (D2), which may be obtainable from blood analysis (M_B) of said patient (P), may be one or more parameters consisting of: arterial blood pH (pHa), pressure of carbon dioxide level (PaCO2), optionally measured transcutaneously (PtcC02), oxygen saturation of arterial blood (SaO2), pressure of oxygen in arterial blood (PpO2), or equivalents thereof and/or combinations thereof. Other parameters applicable, estimated or measurable in blood of a patient may also be applied within the context of the present invention once the general principle and teaching of the invention has been appreciated by the skilled person.
- Particularly, the present invention is advantageous in that the respiratory drive may be estimated without using a measurement of the electrical activity of the diaphragm of the patient, cf.
US patent application 2010/0228142 where this is performed. - In a beneficial embodiment, the control means (CON) may be capable of changing the level from one value to another value in one, or more, volume and/or pressure parameters of the ventilator means (Vt_SET) so as to detect the subsequent changes in the respiratory feedback of said patient by the measurement means. Thus, the changes of ventilator setting are made and afterwards the respiratory feedback of the patient is measured.
- Beneficially, the control means may be alternatively be capable of performing a change in one, or more, volume and/or pressure parameters of the ventilator means (Vt_SET) so as to detect associated changes in the respiratory feedback of said patient by the measurement means while performing said change.
Thus, the changes of Vt_SET are made while changes in respiration are simultaneously measured. - In one embodiment, wherein the control means may be capable of changing one, or more, volume and/or pressure parameters of the ventilator means by changing the inspiratory volume (Vt_SET) and/or the inspiratory pressure set by the ventilator means. It is important to distinguish between the settings for pressure or volume for the mechanical ventilator, and, on the other hand, the actual volume inhaled or expired by the patient, as it will be understood by a person skilled in mechanical ventilation of patients.
- In a second aspect, the present disclosure relates to method for operating a mechanical ventilation system for respiration aid of an associated patient, the method being adapted for estimating one, or more, components of the respiratory drive (R_DRIVE) of said patient, the method comprising:
- providing ventilator means (VENT) capable of mechanical ventilating said patient with air and/or one or more medical gases,
- providing control means (CON), the ventilator means being controllable by said control means by operational connection thereto, and
- providing measurement means (M_G) arranged for measuring the respiratory feedback of said patient in the expired gas in response to the mechanical ventilation, the measurement means being capable of delivering first data (D1) to said control means,
- applying the first data (D1) indicative of changes of respiratory feedback in expired air, and
- applying the second data (D2) indicative of the respiratory feedback in the blood,
- In a third aspect, the present disclosure relates to a computer program product being adapted to enable a computer system comprising at least one computer having data storage means in connection therewith to control a ventilation system according to the first and/or second aspect. Thus, this aspect of the present disclosure may differ from the method of the second aspect in that the third aspect is directed to controlling and/or cooperating with the ventilator means (VENT), the control means (CON), and measurement means (M_G) i.e. instead of providing them.
- This aspect of the present disclosure is particularly, but not exclusively, advantageous in that the present disclosure may be accomplished by a computer program product enabling a computer system to carry out the operations of the ventilation system of the first aspect of the present disclosure when down- or uploaded into the computer system. Such a computer program product may be provided on any kind of computer readable medium, or through a network.
- The individual aspects of the present invention may each be combined with any of the other aspects. These and other aspects of the invention will be apparent from the following description with reference to the described embodiments.
- The method according to the present disclosure will now be described in more detail with regard to the accompanying figures. The figures show one way of implementing the present invention and is not to be construed as being limiting to other possible embodiments falling within the scope of the attached claim set.
-
FIG. 1 is a schematic drawing of a mechanical ventilation system according to the present invention, -
FIG. 2 is a schematic flow chart of a physiological model applied in the present invention, -
FIG. 3 is a model simulated response of a patient to changes in ventilator support, -
FIG. 4 shows three graphs using data collected from a single patient showing the results of the present invention in the graphs, -
FIG. 5 shows seven graphs using data collected from a single patient showing the results of the present invention in the graphs, -
FIG 6 illustrates the set of mathematical model components of a decision support system (DSS) including the mathematical representation of a physiological model of respiratory control, including the effects of chemical and musculature components of total respiratory drive and -
FIG 7 is a schematic flow chart of a method according to the invention. -
FIG. 1 is a schematic drawing of amechanical ventilation system 10 for respiration aid of an associatedpatient 5, P, the system being adapted for estimating the respiratory drive R_DRIVE of the patient. - The system comprises ventilator means 11, VENT capable of mechanical ventilating said patient with air and/or one or more medical gases, e.g. oxygen and/or nitrogen. Conventional ventilator systems currently available may be modified or adapted for working in the context of the present invention. Furthermore, control means 12, CON is comprised in the
system 10, the ventilator means 11 being controllable by said control means 10 by operational connection thereto, e.g. appropriate wirings and interfaces as it will be appreciated by the skilled person working with mechanical ventilation. - Additionally, measurement means 11a, M_G are arranged for measuring the respiratory feedback of said patient in the expired
gas 6 in response to the mechanical ventilation, e.g. respiratory frequency or fraction of expired carbon dioxide commonly abbreviated FECO2, cf. list of some well-known abbreviations below. The measurement means are shown as forming part of the ventilator means 11, but could alternatively form an independent entity with respect to the ventilator means without significantly change the basic principle of the present invention. The measurement means M_G are capable of delivering first data D1 to the control means 12 CON by appropriate connection, by wire, wirelessly or by other suitably data connection. - The control means 12 CON is also capable of operating the ventilation means by providing ventilatory assistance so that said patient 5 P is at least partly breathing spontaneously, and, when providing such ventilatory assistance, the control means being capable of changing one, or more, volume and/or pressure parameters Vt_SET of the ventilator means so as to detect changes in the respiratory feedback in general of the patient by the measurement means M_G.
- The control means is further being arranged for receiving second data D2, preferably obtainable from blood analysis of said patient performed by blood measurement means
M_B 20, the second data being indicative of the respiratory feedback in the blood of said patient, e.g. pHa, PACO2, PA02 etc. Notice that the by blood measurement meansM_B 20 is not necessarily comprised in theventilator system 10 according to the present invention. Rather, thesystem 10 is adapted for receiving second data D2 from such an entity or device as schematically indicated by the connecting arrow. It is however contemplated that a blood measurement means M_B could be comprised in thesystem 10 and integrated therein. In this embodiment, the mechanical ventilator system comprises at least the ventilator meansVENT 10, the measurement meansM_G 11a, and the control meansCON 12. The physiological model MOD is implemented on the control means, e.g. in an appropriate computing entity or device. - In one variant of the invention, the second data D2 could be estimated or guessed values being indicative of the respiratory feedback in the blood of said patient, preferably based on the medical history and/or present condition of the said patient. Thus, values from previously (earlier same day or previous days) could form the basis of such estimated guess for second data D2.
- The control means is adapted for using both the first data D1 indicative of changes of respiratory feedback in
expired air 6, and the second data D2 indicative of the respiratory feedback in theblood 7, in a physiological model MOD capable of estimating one, or more, components of the total respiratory drive R_DRIVE for thepatient 6 as schematically indicated in thebox 13. - The respiratory drive R_DRIVE may be outputted to an appropriate human-
machine interface 13 for displaying the result, e.g. a computer with a screen therefore. Alternatively or additionally, the respiratory drive output R_DRIVE and/or its components, may be communicated to a decisionsupport system DSS 14 for use in connection with mechanical ventilation of patients, optionally for treatment and/or diagnostic purposes. - The principle of this invention is further exemplified in
figures 2 and3 .Figure 2 illustrates an example of the structure a physiological model used in the method. It consists of model components representing the gas exchange of the lungs and the acid-base chemistry of the blood, components representing the acid-base of cerebrospinal fluid (CSF) and the resulting chemical respiratory drive, and the net effect of this chemical drive ventilation according to the action of respiratory muscles. Some of these models exist in the scientific literature [3,4], and the advantage of the present invention is not in the formulation of such models as such but in their use, combined with changes in ventilation to determine total respiratory drive, and/or any of the components related to chemical and muscular drive. -
Figure 3 illustrates the model simulated response of a patient to changes in ventilator support, in this case volume support, represented as the volume of ventilation provided to the patient per breath (Vt), i.e. the variable on the x-axis of each of the subfigures infigure 3 . Alveolar ventilation (VA) could be plotted instead of tidal ventilation with no apparent differences in the method. In particular it simulates the expected respiratory frequency (3a,d), arterial pH (3b,e), and end tidal carbon dioxide (FE'CO2) (3c,f) levels at different levels of volume support (Vt). This response profile can be used to determine the total respiratory drive, and the components of chemical and muscular response. It is important to note that two factors separate this approach from those presented previously. The first is that no measure of the electrical activity of the diaphragm is used to assess the muscular drive to breathing. The second is that the simulated response to changes in ventilator support due to chemical drive can be accounted for by several physiological factors. This is only possible because of the physiological model, including factors contributing to the chemical drive describing: metabolism, and in particular the tissue production of CO2; the acid-base status of blood which modifies peripheral chemoreceptor drive; and the acid base status of CSF which modifies central chemoreceptor drive. These aspects have not been accounted for previously, e.g.US patent application 2010/0228142 which is based upon diaphragm electrical activity.Figures 3a, 3b and 3c of the present application, illustrate two different situations of a normal (solid line) and reduced (dashed line) total respiratory drive. Reducing the total respiratory drive modifies the position of the curves and lines representing these three variables. - Estimation of the parallel shift of the three solid lines to the three dashed lines provides data which enables estimation of changes in the total respiratory drive.
- The apportionment of total respiratory drive to chemical and muscular components can be seen as the difference between
figures 3a-c and 3d-f . In 3a-c, i.e. left hand side offigure 3 , the patient's muscle strength is normal, and the patient can respond adequately to reduction in Vt such that respiratory frequency increases and pH and FE'CO2 remain constant. This pattern of response is consistent with the total respiratory drive being explained by changes in chemical response only. In this case the alveolar ventilation predicted by the chemical drive model (VAexp,figure 6 ) is equivalent to the alveolar ventilation of the patient (VA,figure 6 ).Figures 3d-3f , i.e. the right hand side offigure 3 illustrate the situation where patients muscle strength cannot respond adequately to reduction in volume support and respiratory frequency increases only partially, pH falls and FE'CO2 increases. The alveolar ventilation predicted by the chemical drive (VAexp,figure 6 ) cannot be maintained by the muscles such that the true alveolar ventilation is lower and as a consequence pH falls and FE'CO2 increases. This can be implemented by multiplying the alveolar ventilation predicted by the chemical model with a fraction (fM,figure 6 ) between 0 and 1, where 0 represents no muscle action and 1 muscle action sufficient to allow alveolar ventilation consistent with the respiratory drive. The quantification of the change in total respiratory drive and the components due to chemical and muscular response can be performed either via shifts in the measured curves or by analysing the responses illustrated infigure 3 using mathematical models, similar in structure tofigure 2 and in details tofigure 6 . Estimation of mathematical model parameters can then provide quantification of total respiratory drive and in addition chemical drive and/or muscular drive. It is thus to be understood that any combination of the total drive, the chemical drive (incl. sub-components) and the muscular drive (incl. sub-components) may be provided as a result of applying the present invention as described above, the drive components not being provided as results may possibly be applied as intermediate result(s), e.g. the total respiratory drive may be an intermediate result for finding the components of muscular drive and/or chemical drive. - The overall principle of the method is then that changes in support mode settings which result in changes in tidal volume and respiratory frequency and or acid base status of blood or respiratory gasses can be used to estimate respiratory drive, and optionally apportion that to components related to chemical and muscular drive.
- The present disclosure thus relates to a method for determining respiratory drive and apportioning this to components related to chemical and muscular response.
- The present disclosure comprises measuring the level of ventilation volume or pressure, and one or more of the following variables respiratory frequency, arterial blood pH or carbon dioxide level, and expiratory carbon dioxide levels.
- The present disclosure further comprises changing ventilation volume or pressure and evaluating the changes in the following variables respiratory frequency, arterial blood pH or carbon dioxide level.
- The method further comprises analysis of these data in terms of mathematical models or curve shifts to determine respiratory drive.
- The method further comprises analysis of these data in terms of mathematical models or curve shifts to determine the component of respiratory drive due to chemical response.
- The method further comprises that measurements of metabolism and acid-base status of the blood or CSF can be accounted for in the component of respiratory drive due to chemical response.
- The method further comprises analysis of these data in terms of mathematical models or curve shifts to determine the component of respiratory drive due to response of the muscular system involved in breathing.
- Advantageously, the level of carbon dioxide in respiratory gas may be provided by measurements of FECO2, PECO2, FE'CO2, PE'CO2 or other equivalent measures available to the skilled person.
- The present invention may be beneficially applied when the individual is a normal person, a person under mechanical ventilation in general, or suffers from one or more respiratory diseases or abnormalities, including primary and secondary lung diseases, such as chronic obstructive pulmonary disease (COPD), acute lung injury, acute respiratory distress syndrome, pulmonary edema, or asthma. Other related or similar diseases/conditions for which the present invention may be advantageously applied are also contemplated.
- The invention can be implemented by means of hardware, software, firmware or any combination of these. The invention or some of the features thereof can also be implemented as software running on one or more data processors and/or digital signal processors.
- The individual elements of an embodiment of the invention may be physically, functionally and logically implemented in any suitable way such as in a single unit, in a plurality of units or as part of separate functional units. The invention may be implemented in a single unit, or be both physically and functionally distributed between different units and processors.
- Although the present invention has been described in connection with the specified embodiments, it should not be construed as being in any way limited to the presented examples. The scope of the present invention is to be interpreted in the light of the accompanying claim set. In the context of the claims, the terms "comprising" or "comprises" do not exclude other possible elements or steps. Also, the mentioning of references such as "a" or "an" etc. should not be construed as excluding a plurality. The use of reference signs in the claims with respect to elements indicated in the figures shall also not be construed as limiting the scope of the invention. Furthermore, individual features mentioned in different claims, may possibly be advantageously combined, and the mentioning of these features in different claims does not exclude that a combination of features is not possible and advantageous.
- It should be noted that embodiments and features described in the context of one of the aspects of the present invention also apply to the other aspects of the invention.
- The invention will now be described in further details in the following non-limiting examples.
-
Figures 4 and5 exemplify the technique using data collected from two patients (one for each figure). Infigure 4 , plots are shown of changes in tidal volume (Vt) against A) respiratory frequency, B) end tidal CO2 and C) arterial pH. The dashed curve infigure 4A represents the model simulated response of these variables assuming normal muscular and chemical response, normal values of metabolism, e.g. rate of tissue CO2 production, and normal values of the acid-base status of blood and CSF. Stars, solid circles, crosses, diagonal crosses, open circles and triangles on plots 4A-C represent data collected at different values of Vt, with each symbol representing a different value of ventilator setting on the ventilator, Vt_SET. It should be noted this data has been collected and plotted with volume as a variable, but in clinical practise the pressure is often applied as the variable instead. This is however equivalent as the skilled person will understand, and does not change the overall principle and teaching of the present invention. - Solid curves on plots 4A-C represent model simulations when the chemical response is adapted to the individual patient, but assuming normal muscular response. This adaptation to chemical response includes: a) inputting the rate of CO2 production into the physiological model for that individual patient, where CO2 production can be measured from respiratory gas composition and flow; b) inputting the acid-base status of blood into the model and from this calculating the state of CSF acid-base status, where acid-base status is measured, for example, from a blood sample. In addition any factors in the response is not explained by changes in CO2 production or abnormal acid-base status are then accounted for by fitting the physiological mathematical model to the measured data shown on
figure 4A . This model fitting can be performed using standard least-square techniques where model parameters such as those describing thresholds or gains in central or peripheral chemical drive are adjusted until the model provides a best fit to the data as the minimum sum of squared differences between model predictions and measured data. This model fitting can be performed for data collected at a single setting of mechanical ventilation, or over a data set collected at several different settings as illustrated by each of the symbols onfigure 4A . - In
figure 5 , plots are shown of changes in tidal volume (Vt) against (a and e) respiratory frequency, and (b and f) arterial pH, and (c and g) end tidal CO2. The dashed curve in all subplots offigure 5 represent the model simulated response of these variables assuming normal muscular and chemical response, normal values of metabolism, e.g. rate of tissue CO2 production, and normal values of the acid-base status of blood and CSF. Triangles, open circles, diagonal crosses, vertical crosses, diamonds and stars represent data collected or model simulations at different values of Vt, with each symbol representing a different value of ventilator setting on the ventilator, Vt_SET. Measured data points are connected with solid lines, and model simulated points are connected with dotted lines. It should be noted these data have been collected and plotted with volume as a variable as either tidal volume or alveolar ventilation, but in clinical practise pressure is often applied as the variable instead. This is however equivalent as the skilled person will understand, and does not change the overall principle and teaching of the present invention. Error bars are represented where points are repeated measures. Forfigures 5a-c these figures represent model simulations when the chemical response is adapted to the individual patient, but assuming normal muscular response (fM =1). This adaptation to chemical response includes: a) inputting the rate of CO2 production into the physiological model for that individual patient, where CO2 production can be measured from respiratory gas composition and flow; b) inputting the acid-base status of blood into the model and from this calculating the state of CSF acid-base status, where acid-base status is measured, for example, from a blood sample. In addition any factors in the response is not explained by changes in CO2 production or abnormal acid-base status are then accounted for by fitting the physiological mathematical model to the measured data shown onfigures 5 a-c . This model fitting can be performed using standard least-square techniques where model parameters such as those describing thresholds or gains in central or peripheral chemical drive are adjusted until the model provides a best fit to the data as the minimum sum of squared differences between model predictions and measured data. This model fitting can be performed for data collected at a single setting of mechanical ventilation, or over a data set collected at several different settings as illustrated by each of the symbols onfigures 5 a-c . It can be seen for this patient that fitting the chemical drive model alone results in simulations (symbols connected with dotted lines) which match measurements (symbols connected with solid lines) very well for the highest 4 levels of Vt, i.e. for levels represented by triangles, open circles, diagonal crosses, and vertical crosses. Data describing the lowest 2 levels of Vt (symbols starts and diamonds), where the patient is likely most stressed, are not described well by the chemical model with model simulated of respiratory frequency too high, model simulated pHa too high and model simulated FetCO2 too low. -
Figure 5 e-g includes model simulations (symbols connected with dotted lines) when the chemical response is adapted to the individual patient, along with adaptation to muscular response. It can be seen for this patient that fitting the chemical drive model and muscular response results in simulations (symbols connected with dotted lines) which match measurements (symbols connected with solid lines) at all levels of Vt. To do so the alveolar ventilation calculated by the chemical model is modified by a constant fraction. This fraction is shown infigure 5d for each of the values of Vt. For the highest 4 levels of Vt, i.e. for levels represented by triangles, open circles, diagonal crosses, and vertical crosses the value of the fraction (fM) is 1, indicating no correction is required. For the lowest 2 levels of Vt (stars and diamonds), where the patient is likely most stressed, the alveolar ventilation calculated by the chemical model is reduced, requiring a value of the fraction fM = approximately 0.7 to account for muscle fatigue. - These cases represent mechanically ventilated patients admitted to an intensive care unit Informed consent was obtained and the study was approved by the local Ethics Committee.
- The model of chemical drive was adapted to the patient to describe the respiratory frequency, end tidal CO2 and arterial pH changes following changes in Vt as described above accounting for CO2 production, acid-base status in blood and CSF and by fitting the model to the data to estimate parameters describing the threshold and gain of central chemoreceptor response. The shift illustrated by the arrow in
figure 4a (labelled I) represents the change in chemical respiratory drive from normal seem in this patient due to all these factors in the mathematical model. - Since the solid curves represent model simulations when the chemical response is adapted to the individual patient, but assuming normal muscular response, then the shift illustrated by the arrows in plots 4b and 4c, and labelled II, represents changes in pH and PCO2 characteristic of muscle fatigue and hence reduced muscle drive. These shifts can be represented graphically as here, or by using values of physiological model parameters. These parameters can, for example, describe weighting of the calculated chemical drive so as to reduce the effect of chemical response.
- The differences between model simulations (symbols connected with dashed lines) illustrated in
figures 5e-g and the dashed lines on these figures represent the changes in chemical respiratory drive from normal and all other factors previously discussed plus the effects of muscle fatigue seen in this patient. The difference between model simulations (symbols connected by dotted lines) infigures 5 a-cand figures 5 e-g represents the differences characteristic of muscle fatigue and hence reduced muscle drive. These differences are quantified in this figure by estimating the factor fM which weighs the expected alveolar ventilation given the chemical drive (VAexp,figure 6 ) to give the patients true alveolar ventilation given their muscular response (VA,figure 6 ). - In these examples, it is shown that data describing the response to changes in respiratory tidal volume can be used to identify changes in respiratory drive, including those that can be apportioned to changes in chemical and muscular response and that chemical drive can be measured components accounting for metabolism and acid-base status and model parameters describing regulation of chemoreceptors.
-
FIG. 6 illustrates the set of mathematical model components of a decision support system (DSS) including the mathematical representation in the form of physiological model of respiratory control and muscle function that may be applied in the context of the present invention. For further background on these models, the skilled person is referred to references [1-6] listed below. - The DSS includes models of: pulmonary gas exchange (A); acid-base status and oxygenation of blood (B); acid-base status of CSF (C); circulation and blood in arterial and mixed venous pools (D); interstitial fluid and tissue buffering, and metabolism (E); chemoreflex model of respiratory control (F); muscular function (G); and ventilation (H).
-
Figure 6 illustrates the set of mathematical model components of INVENT including the mathematical representation of respiratory control (A-H).Figure 6A illustrates the structure of the model of ventilation and pulmonary gas exchange.Figure 6B illustrates the structure of the model of oxygenation and acid-base status in the blood.Figure 6 C illustrates Duffin's model of CSF with appropriate model constants [3, 4]. This model includes mass-action equations describing water, phosphate and albumin dissociation plus the formation of bicarbonate and carbonate, and an equation representing electrical neutrality (equations 1-6). In addition, equation (7) is used to describe the equilibration of PCO2 with arterial blood across the blood-brain barrier. Equation (8) is a modification to Duffin's model which allows calibration of the CSF to conditions where blood bicarbonate, and hence buffer base (BB) or strong ion difference (SID) are modified, such as metabolic acidosis where blood bicarbonate is reduced, or chronic lung disease where blood bicarbonate is increased. - The model illustrated in
figure 6 includes compartments representing CO2 transport and storage including the arterial and venous compartments, and circulation represented as cardiac output (Q) (figure 5D ). -
Figure 6E illustrates the model of interstitial fluid and tissue buffering, and metabolism included in the system. This includes oxygen consumption (VO2) and carbon dioxide production (VCO2). -
Figure 6F illustrates the model of respiratory control of Duffin, i.e. equations 9 - 12. Alveolar ventilation is modeled as a peripheral and central chemoreflex response to arterial and cerebrospinal fluid (CSF) hydrogen ion concentration ([H+ a] and [H+ csf]) plus wakefulness drive. Equation (9) describes the peripheral drive (Dp) as a linear function of the difference between [H+ a] and the peripheral threshold (Tp). The slope of this function (Sp) represents the sensitivity of the peripheral chemoreceptors. - Equation (11) describes central drive (Dc) as a linear function of the difference between [H+ csf] and the central threshold (Tc). The slope of this function (Sc) represents the sensitivity of central chemoreceptors. Equation (12) describes the expected alveolar ventilation as the sum of the two chemoreflex drives and the wakefulness drive (Dw).
-
Figure 6G represents the muscular action on alveolar ventilation. The calculated alveolar ventilation from the respiratory control equations (figure 6F ) is scaled according to a constant (0<fM≤1) to calculate the alveolar ventilation applied by the muscles. A value of fM <1 illustrates that the muscle cannot deliver the respiratory drive calculated by the chemical control model. -
Figure 6H ,equation 14, describes the minute ventilation as alveolar ventilation plus ventilation of the dead space, that is equal to the product of tidal volume (Vt) and respiratory frequency (f). - The model described above can be used to simulate respiratory control. The model enables simulation of the control of alveolar ventilation taking into account pulmonary gas exchange, blood and CSF acid-base status, circulation, tissue and interstitial buffering, and metabolism.
-
FIG 7 is a schematic flow chart of a method according to the invention. The present disclosure thus relates to a method for operating amechanical ventilation system 10 for respiration aid of an associatedpatient 5, P, the method being adapted for estimating the respiratory drive R_drive of said patient, the method comprising: - S1 providing ventilator means VENT capable of mechanical ventilating said patient with air and/or one or more medical gases,
- S2 providing control means CON, the ventilator means being controllable by said control means by operational connection thereto, and
- S3 providing measurement means M_G arranged for measuring the respiratory feedback of said patient in the expired gas in response to the mechanical ventilation, the measurement means being capable of delivering first data D1 to said control means,
- applying the first data D1 indicative of changes of respiratory feedback in expired air, and
- applying the second data D2 indicative of the respiratory feedback in the blood,
-
- CSF
- Cerebral spinal fluid
- Vt
- Respiratory volume in a single breath, tidal volume
- Vt_SET
- Respiratory volume settings for mechanical ventilation, tidal volume
- FECO2
- Fraction of carbon dioxide in expired gas.
- FE'CO2
- Fraction of carbon dioxide in expired gas at the end of expiration.
- PECO2
- Partial pressure of carbon dioxide in expired gas.
- PE'CO2
- Partial pressure of carbon dioxide in expired gas at the end of expiration.
- RR
- respiratory frequency (RR) or, equivalently, duration of breath (including duration of inspiratory or expiratory phase)
- pHa
- Arterial blood pH
- PaCO2
- Pressure of carbon dioxide level,
- SaO2
- Oxygen saturation of arterial blood
- PpO2
- Pressure of oxygen in arterial blood
- In short, the present disclosure relates to a
system 10 and a corresponding method for estimating the respiratory drive,R_DRIVE, of mechanically ventilated patients, and for preferably apportioning this respiratory drive into one, or more, components related to the chemical drive - i.e. the drive due to the chemoreceptor response- and/or the muscular drive - i.e. the contraction of respiratory muscles, for example the diaphragm. The principle of the invention is that respiratory drive can be obtained from measuring the patient's response to small changes in mechanical ventilation settings, Vt_SET, and that this can be apportioned into chemical and/or muscular effects depending upon the changes in respiratory frequency, and/or arterial or end tidal CO2 levels, and/or arterial blood pH, as indicated inFigure 1 . -
- 1. The Acute Respiratory Distress Syndrome (ARDS) Network (2000) Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl. J Med. 342:1301-1308.
- 2. L. Brochard and A. W. Thille, "What is the proper approach to liberatng the weak from mechanical ventilation?," Critical Care, vol. 37, pp. S410-S415, 2009.
- 3. Duffin, J. "The role of the central chemoreceptors: A modeling perspective." Respiratory Physiology and Neurobiology 173 (2010): 230-243.
This reference is particularly relevant for the models on acid-base status of CSF (C), and respiratory drive (F) as shown inFigure 6 . - 4. Duffin, J. "Role of acid-base balance in the chemoreflex control of breathing." J Appl Physiol 99 (2005): 2255-2265.
This reference is also particularly relevant for the models on acid-base status of CSF (C) and respiratory drive (F) as shown inFigure 6 . - 5. S. E. Rees, C. Allerød, D. Murley, Y. Zhao, B. W. Smith, S. Kjaergaad, P. Thorgaad and S. Andreassen, "Using physiological models and decision theory for selecting appropriate ventilator settings," Journal of Clinical Monitoring and Computing, vol. 20, pp. 421-429, 2006.
- 6. S. E. Rees, "The Intelligent Ventilator (INVENT) project: The role of mathematical models in translating physiological knowledge into clinical practice," Computer Methods and Programs in Biomedicine, vol. 104S, pp. S1-S29, 2011. This reference is particularly relevant for the models of pulmonary gas exchange (A); acid-base status and oxygenation of blood (B); circulation and blood in arterial and mixed venous pools (D); interstitial fluid and tissue buffering, and metabolism (E), as shown in
Figure 6 .
the control means further being arranged for receiving second data (D2), preferably obtainable from blood analysis of said patient, said second data being indicative of the respiratory feedback in the blood of said patient,
the control means being adapted for using:
the control means further being arranged for receiving second data (D2), preferably obtainable from blood analysis of said patient, said second data being indicative of the respiratory feedback in the blood of said patient,
the control means being adapted for:
the control means further being arranged for receiving second data (D2), preferably obtainable from blood analysis of said patient, said second data being indicative of the respiratory feedback in the blood of said patient,
the control means being adapted for:
Claims (17)
- A mechanical ventilation system (10) for respiration aid of an associated patient (5, P) comprising:- ventilator means (11, VENT) for mechanical ventilation of the patient with air and/or one or more medical gases,- measurement means (11a, M_G) configured for measuring the respiratory feedback of said patient in the expired gas (6) in response to the mechanical ventilation, and- control means (12, CON) for controlling the ventilator means,
wherein the control means is configured for- operating the ventilator means by providing ventilatory assistance such that the patient is at least partly breathing spontaneously,- changing one or more volume and/or pressure parameters (Vt_SET) of the ventilator means during ventilatory assistance to detect changes in the respiratory feedback of said patient by the measurement means,- receiving∘ first data (D1) from the measurement means indicative of changes of respiratory feedback in expired air (6), and∘ second data (D2) indicative of the respiratory feedback in the blood of said patient,the mechanical ventilation system characterized in that the control means is configured for- estimating one or more components (R_MUSC, RCHEM) of the total respiratory drive (R_DRIVE) of the patient by using the first data (D1) and the second data (D2) in a physiological model (MOD). - The mechanical ventilation system according to claim 1, wherein the physiological model (MOD) comprises a component of the total respiratory drive being indicative of muscular response (R_MUSC).
- The mechanical ventilation system according to claim 1 or 2, wherein the measurement means and the control means are further arranged to measure an indication of muscular response (R_MUSC).
- The mechanical ventilation system according to claim 1 or 2, wherein the physiological model (MOD) comprises a component of the total respiratory drive being indicative of a chemical response (R_CHEM), preferably a subcomponent indicative of the central chemical response and a subcomponent indicative of the peripheral chemical response.
- The mechanical ventilation system according to any of claims 1-4, wherein the control means is configured for estimating both a muscular response (R_MUS) and a chemical response (R_CHEM) forming part of the total respiratory drive (R_DRIVE).
- The mechanical ventilation system according to any of claims 1-5, wherein the control means is configured for estimating a muscular response (R_MUS) and a chemical response (R_CHEM) by initially assuming one of the two responses; muscular response (R_MUS) or chemical response (R_CHEM), being a certain approximately constant level, preferably a normal level for said patient, and then subsequently iteratively solving for the other response.
- The mechanical ventilation system according to claim 5, wherein the muscular response is initially assumed constant, preferably a normal level for said patient, and the chemical response is estimated, the estimated chemical response being subsequently applied for modelling a respiratory feedback to be compared with a measured respiratory feedback of the patient, any deviation therebetween being a measure for an inadequate response capability of the patient.
- The mechanical ventilation system according to claim 1, wherein the second data (D2) used in the physiological model (MOD) is indicative for oxygenation and/or acid-base status of the blood, preferably being related to the influence of the acid-base status on the cerebrospinal fluid (CSF).
- The mechanical ventilation system according to claim 1, wherein the second data (D2) used in the physiological model (MOD) is indicative for the metabolism of said patient, preferably the tissue production of carbon dioxide (CO2).
- The mechanical ventilation system according to any of claim 1-9, wherein the physiological model (MOD), which is capable of estimating one or more components of the total respiratory drive (R_DRIVE) for the patient, is operationally connected to a medical decision support system (DSS), preferably for application in mechanical ventilation.
- The mechanical ventilation system according to claim 1, wherein the measurement means (M_G) is configured for measuring one or more of the following parameters consisting of: respiratory frequency (RR) or, equivalently, duration of breath (including duration of inspiratory or expiratory phase), and expiratory carbon dioxide levels (FECO2), fraction of carbon dioxide in expired gas at the end of expiration, (FE'CO2), partial pressure of carbon dioxide in expired gas (PECO2), partial pressure of carbon dioxide in expired gas at the end of expiration (PE'CO2), or equivalents thereof and/or combinations thereof.
- The mechanical ventilation system according to 1, wherein the second data (D2), which is preferably obtainable from blood analysis (M_B) of said patient (P), is one or more parameters consisting of: arterial blood pH (pHa), pressure of carbon dioxide level (PaCO2), optionally measured transcutaneously (PtcC02), oxygen saturation of arterial blood (SaO2), pressure of oxygen in arterial blood (PpO2), or equivalents thereof and/or combinations thereof.
- The mechanical ventilation system according to claim 1, wherein the respiratory drive is estimated without using a measurement of the electrical activity of the diaphragm of the patient.
- The mechanical ventilation system according to claim 1, wherein the control means (CON) is configured for changing the level from one value to another value in one or more volume and/or pressure parameters of the ventilator means (Vt_SET) thereby detecting the subsequent changes in the respiratory feedback of said patient by the measurement means.
- The mechanical ventilation system according to claim 1, wherein the control means is configured for performing a change in one or more volume and/or pressure parameters of the ventilator means (Vt_SET) thereby detecting associated changes in the respiratory feedback of said patient by the measurement means while performing said change.
- The mechanical ventilation system according to claim 1, wherein the control means is configured for changing one or more volume and/or pressure parameters of the ventilator means by changing the inspiratory volume (Vt_SET) and/or the inspiratory pressure set by the ventilator means.
- A computer program product being adapted to enable a computer system comprising at least one computer having data storage means in connection therewith to control a ventilation system (10) according to claim 1.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201370283 | 2013-05-24 | ||
DKPA201470120 | 2014-03-12 | ||
PCT/DK2014/050143 WO2014187465A1 (en) | 2013-05-24 | 2014-05-22 | A system and a corresponding method for estimating respiratory drive of mechanically ventilated patients |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3003443A1 EP3003443A1 (en) | 2016-04-13 |
EP3003443B1 true EP3003443B1 (en) | 2019-12-18 |
Family
ID=50780458
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14725961.8A Active EP3003443B1 (en) | 2013-05-24 | 2014-05-22 | A system and a corresponding method for estimating respiratory drive of mechanically ventilated patients |
Country Status (6)
Country | Link |
---|---|
US (1) | US11020551B2 (en) |
EP (1) | EP3003443B1 (en) |
CN (1) | CN105705189B (en) |
DK (1) | DK3003443T3 (en) |
ES (1) | ES2775208T3 (en) |
WO (1) | WO2014187465A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20120428A1 (en) * | 2012-03-19 | 2013-09-20 | Giacomo Bellani | APPARATUS FOR ASSISTED VENTILATION AND ITS ADJUSTMENT METHOD |
EP4235689A3 (en) | 2013-11-15 | 2024-01-24 | Covidien LP | Decision support system for lung ventilator settings |
EP3833254B1 (en) * | 2018-08-07 | 2024-10-02 | Rostrum Medical Innovations Inc. | System and method for monitoring a blood flow that does not interact with ventilated lungs of a patient |
CN109806472A (en) * | 2019-03-01 | 2019-05-28 | 北京谊安医疗系统股份有限公司 | Automatically adjust the method, apparatus and Breathing Suppotion machine of mechanical ventilation parameters |
EP3721804A1 (en) * | 2019-04-11 | 2020-10-14 | Obi ApS | Identification and quantification of a ventilatory distubance causing incorrect measurement of arterial acid-base status |
CN114849007B (en) * | 2022-05-05 | 2023-04-18 | 广州蓝仕威克医疗科技有限公司 | Method and system for solving over ventilation based on respirator device |
CN117323525B (en) * | 2023-12-01 | 2024-02-23 | 南京沪家医疗科技有限公司 | Pressure control method and device of breathing machine |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4867152A (en) * | 1987-10-09 | 1989-09-19 | The Boc Group, Inc. | Respiratory therapy apparatus with selective display of parameter set points |
DE3817053A1 (en) * | 1988-05-19 | 1989-11-30 | Draegerwerk Ag | METHOD FOR CONTROLLING A VENTILATION DEVICE AND DEVICE THEREFOR |
EP1156846A1 (en) * | 1999-02-03 | 2001-11-28 | University Of Florida | Method and apparatus for nullifying the imposed work of breathing |
WO2001000264A1 (en) | 1999-06-30 | 2001-01-04 | University Of Florida Research Foundation, Inc. | Ventilator monitor system and method of using same |
US6553992B1 (en) * | 2000-03-03 | 2003-04-29 | Resmed Ltd. | Adjustment of ventilator pressure-time profile to balance comfort and effectiveness |
EP3245949A1 (en) * | 2006-01-19 | 2017-11-22 | Maquet Critical Care AB | Method and system for determining dynamically respiratory features in spontaneously breathing pateints receiving mechanical ventilatory assist |
WO2007140512A1 (en) * | 2006-06-05 | 2007-12-13 | Resmed Ltd | Systems and/or methods for calibration-less devices or less expensive calibration devices for treating sleep-disordered breathing |
US20080295839A1 (en) * | 2007-06-01 | 2008-12-04 | Habashi Nader M | Ventilator Apparatus and System of Ventilation |
US20100071696A1 (en) * | 2008-09-25 | 2010-03-25 | Nellcor Puritan Bennett Llc | Model-predictive online identification of patient respiratory effort dynamics in medical ventilators |
FR2937850B1 (en) * | 2008-11-03 | 2011-12-09 | Assistance Publique Hopitaux Paris | SYSTEM FOR DETECTING THE RESPIRATORY MUSCLE ACTIVITY OF A PATIENT UNDER RESPIRATORY ASSISTANCE. |
US8554298B2 (en) * | 2010-09-21 | 2013-10-08 | Cividien LP | Medical ventilator with integrated oximeter data |
US10390711B2 (en) * | 2010-11-26 | 2019-08-27 | Mermaid Care A/S | Automatic lung parameter estimator for measuring oxygen and carbon dioxide gas exchange |
JP6441572B2 (en) * | 2011-01-25 | 2018-12-19 | アペリス・ホールディングス,エルエルシー | Apparatus and method for assisting breathing |
US9629971B2 (en) * | 2011-04-29 | 2017-04-25 | Covidien Lp | Methods and systems for exhalation control and trajectory optimization |
US20140000606A1 (en) * | 2012-07-02 | 2014-01-02 | Nellcor Puritan Bennett Llc | Methods and systems for mimicking fluctuations in delivered flow and/or pressure during ventilation |
CN102949770B (en) * | 2012-11-09 | 2015-04-22 | 张红璇 | External diaphragm pacing and breathing machine synergistic air supply method and device thereof |
CN103893866B (en) * | 2012-12-27 | 2016-06-15 | 北京谊安医疗系统股份有限公司 | A kind of intelligent breathing machine removes machine method and device |
-
2014
- 2014-05-22 CN CN201480042114.0A patent/CN105705189B/en active Active
- 2014-05-22 WO PCT/DK2014/050143 patent/WO2014187465A1/en active Application Filing
- 2014-05-22 US US14/893,446 patent/US11020551B2/en active Active
- 2014-05-22 EP EP14725961.8A patent/EP3003443B1/en active Active
- 2014-05-22 ES ES14725961T patent/ES2775208T3/en active Active
- 2014-05-22 DK DK14725961.8T patent/DK3003443T3/en active
Non-Patent Citations (2)
Title |
---|
DAN S KARBING ET AL: "Retrospective evaluation of a decision support system for controlled mechanical ventilation", MEDICAL & BIOLOGICAL ENGINEERING & COMPUTING, SPRINGER, BERLIN, DE, vol. 50, no. 1, 22 November 2011 (2011-11-22), pages 43 - 51, XP019995072, ISSN: 1741-0444, DOI: 10.1007/S11517-011-0843-Y * |
STEPHEN E REES ET AL: "The Intelligent Ventilator Project: Application of Physiological Models in Decision Support", 2 July 2011, ECCV 2016 CONFERENCE; [LECTURE NOTES IN COMPUTER SCIENCE; LECT.NOTES COMPUTER], SPRINGER INTERNATIONAL PUBLISHING, CHAM, PAGE(S) 149 - 158, ISBN: 978-3-642-01969-2, ISSN: 0302-9743, XP019164371 * |
Also Published As
Publication number | Publication date |
---|---|
US11020551B2 (en) | 2021-06-01 |
WO2014187465A1 (en) | 2014-11-27 |
DK3003443T3 (en) | 2020-03-23 |
EP3003443A1 (en) | 2016-04-13 |
US20160121064A1 (en) | 2016-05-05 |
CN105705189B (en) | 2018-09-21 |
CN105705189A (en) | 2016-06-22 |
ES2775208T3 (en) | 2020-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3003443B1 (en) | A system and a corresponding method for estimating respiratory drive of mechanically ventilated patients | |
US20200327993A1 (en) | Mechanical ventilation system for respiration with decision support | |
US11728023B2 (en) | Decision support system for lung ventilator settings | |
US10390711B2 (en) | Automatic lung parameter estimator for measuring oxygen and carbon dioxide gas exchange | |
US10842411B2 (en) | Non-invasive estimation of intra-pleural pressure and/or computation of work of breathing based on a non-invasive estimation of intra-pleural pressure | |
US20140235959A1 (en) | Methods and algorithms for supervisory closed-loop determination of optimized scheduling of ventilator weaning trials | |
US20240339210A1 (en) | Intelligent medical monitoring of a patient | |
Cross et al. | A comparison of methods used to quantify the work of breathing during exercise | |
Larraza et al. | A mathematical model approach quantifying patients’ response to changes in mechanical ventilation: Evaluation in volume support | |
US20220168527A1 (en) | Method and apparatus to guide mechanical ventilation | |
WO2020207981A1 (en) | Identification and quantification of a ventilatory disturbance causing incorrect measurement of arterial acid-base status | |
Jong | Dynamic modelling of the physiology of breathing to improve mechanical ventilation | |
US11839717B2 (en) | Minute volume and carbon dioxide clearance as surrogates for EtCO2 in automatic ventilation | |
Kretschmer et al. | A mathematical model of gas exchange predicting CO2 response to respiratory rate changes | |
Jensen et al. | An evaluation of end-tidal CO 2 change following alterations in ventilation frequency | |
Tawhai et al. | Breathing easier: model-based decision support for respiratory care looks beyond tomorrow | |
Sundaresan et al. | Prediction of Cardiac Output changes with response to PEEP on patients under mechanical ventilation | |
Lucangelo et al. | Dead space | |
Tehrani et al. | Continuous Positive Airway Pressure treatment of premature infants; application of a computerized decision support system | |
Mark et al. | Parameterization of Respiratory Peripheral Drive | |
Kretschmer et al. | Time course of etCO 2 response to alterations in respiration rate predicted by a mathematical model of human gas exchange |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20151221 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20180214 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20190704 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602014058545 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1213896 Country of ref document: AT Kind code of ref document: T Effective date: 20200115 |
|
REG | Reference to a national code |
Ref country code: FI Ref legal event code: FGE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: STOLMAR AND PARTNER INTELLECTUAL PROPERTY S.A., CH |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20200317 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20191218 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191218 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200318 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191218 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200318 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200319 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191218 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191218 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191218 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2775208 Country of ref document: ES Kind code of ref document: T3 Effective date: 20200724 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200513 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191218 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191218 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191218 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191218 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200418 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191218 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191218 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602014058545 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1213896 Country of ref document: AT Kind code of ref document: T Effective date: 20191218 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20200921 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191218 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191218 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191218 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191218 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20200531 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200522 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200531 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191218 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191218 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191218 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191218 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20220517 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FI Payment date: 20220428 Year of fee payment: 9 Ref country code: CH Payment date: 20220425 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20230420 Year of fee payment: 10 Ref country code: IE Payment date: 20230420 Year of fee payment: 10 Ref country code: FR Payment date: 20230420 Year of fee payment: 10 Ref country code: ES Payment date: 20230601 Year of fee payment: 10 Ref country code: DK Payment date: 20230419 Year of fee payment: 10 Ref country code: DE Payment date: 20230419 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20230420 Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230523 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230531 Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230522 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230531 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: PC2A Owner name: COVIDIEN LP Effective date: 20240425 |